As part of CMS’ movement to better healthcare, Sharecare aims to deliver immediate value to people through digital solutions that are secure, user-centered, and connected. Alongside other industry ...

Ecully, July 30, 2025 – 7 p.m. The Board of Directors of Spineway, meeting on July 30, 2025 under the chairmanship of Stéphane Le Roux, approved the financial statements for the six months to June 30, ...

LOS ANGELES, July 29, 2025 (GLOBE NEWSWIRE) -- UN Peace Ambassador Dr. Michael K. Obeng, the founder of Restore Worldwide, ...

SupplyCopia's participation at AHRMM25 builds on the company's continued commitment to transforming healthcare supply chains through innovative AI solutions. The company's technology has helped health ...

Both the 20mg and 30mg onvansertib arms demonstrated an early separation of the PFS curves compared to the control arm at a ...

Executive officers and members of Tevogen’s Board of Directors collectively hold over 74% of the Company’s outstanding shares. This substantial insider ownership reflects the leadership’s deep ...

Lecanemab received traditional approval in the U.S. in July 2023 for the treatment of early Alzheimer's disease (AD). This retrospective study was conducted to investigate the actual state of ...

The Canadian Red Cross extends its gratitude to Gary Slaight and The Slaight Family Foundation for a $1 million contribution over two years, in support of humanitarian efforts in Cox’s Bazar, ...

These two clearances mark an important step forward for Bioventus and represent a substantial growth opportunity as the Company looks to expand in the PNS market, which is currently estimated to be ...

About BioNexus Gene Lab Corp. BGLC is an innovation-led life-sciences platform – bringing together precision diagnostics, cross-border expertise, and AI data development. Listed on Nasdaq, BGLC’s ...

Title: Results from a Phase 1 expansion cohort of solnerstotug (pH-selective anti-VISTA antibody) combined with cemiplimab in patients with advanced solid tumors resistant to prior PD- (L)1 therapy ...

VLTR-559, a long-acting anti-VEGF therapy, could reduce dosing frequency for the treatment of wet AMD to twice-yearly, as compared to every eight to twelve weeks for standard-of-care anti-VEGFs ...